Abbott Laboratories (ABT), VIVUS, Inc. (VVUS) – It’s Official: Obesity Is a Disease

According to the American Medical Association, obesity is now officially a disease.

A highly preventable disease, but a disease nonetheless.

I think that’s probably the right call. For many people, lung cancer is highly preventable — just don’t smoke — but it would be weird not to call lung cancer a disease.

The decision wasn’t without debate, though. In fact, the AMA’s Council on Science and Public Health actually recommended against calling obesity a disease. The main issue revolves around using body mass index, or BMI, as a measure for obesity. A 5’11” man who weighs 215 pounds is technically obese, but he may be fairly healthy and probably doesn’t need to be treated aggressively. There was also a worry that calling obesity a disease might let people off the hook in trying to prevent it in the first place.

Ultimately, the AMA’s House of Delegates ignored the council’s recommendation, voting in favor of a resolution to recognize obesity as a disease.

Great news for these companies
In the past, there’s been a distinct lack of interest in treating obesity. Doctors felt that it was mostly an aesthetic issue, so drugs to treat obesity had to be very safe. The severity of the disease is always a consideration in the acceptability of how severe side effects can be.

More recently, it’s become clear that obesity is a risk factor for other issues including type 2 diabetes and high blood pressure, making prevention and treatment a higher priority.

Abbott Laboratories (NYSE:ABT)

Unfortunately, having Wyeth’s Fen-Phen and Abbott Laboratories (NYSE:ABT)‘s Meridia pulled off the market because of side effect issues made many doctors wary of treatments. VIVUS, Inc. (NASDAQ:VVUS) got off to a very slow start, selling just $4.1 million of its obesity drug Qsymia in the first quarter, its second full quarter on the market.

The AMA’s decision should shed light on the issue, stressing treatment. But I continue to think it’s going to take time before doctors have enough experience prescribing Qsymia and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai’s Belviq that they’re prescribing them to a majority of their obese patients. Clinical trial data is nice, but there’s no substitute for real-life experience on a few select patients.

Perhaps more importantly, the AMA’s decision could affect reimbursement for the drugs. VIVUS, Inc. (NASDAQ:VVUS) and Eisai are slowly gaining coverage from private insurersm, and an endorsement by the AMA certainly won’t hurt their efforts. VIVUS, Inc. (NASDAQ:VVUS) is shooting for 50% coverage of people covered by private insurance by the end of the year  The AMA’s endorsement may also affect government coverage. A bill was recently introduced into Congress that would provide coverage of obesity drugs by Medicare.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) , the third player whose obesity drug could be approved next year, might be hitting the market at the perfect time, just as all the kinks are worked out. And if its drug Contrave is approved, it’ll be the only one to have shown that it doesn’t cause cardiovascular problems.

The article It’s Official: Obesity Is a Disease originally appeared on Fool.com.

Fool contributor Brian Orelli plans to go for a run after finishing this article. He has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!